Atlas Trials

Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

Clinical trial NCT04167345 · TERMINATED

Trial details

NCT number
NCT04167345
Sponsor
Vertex Pharmaceuticals Incorporated
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Alpha 1-Antitrypsin Deficiency
Start date
2020-01-13
Primary completion
2020-11-14
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.